Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-Adjusted R-BAC in Older MCL
NCT01662050Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and cytarabine in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Complete Remission Rate at 6 months and Occurrence of Relevant Toxicity or Stop Treatment Criteria at 6 months. Started Mar 2012; status: completed.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01662050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662050.